Artificial intelligence (AI) rapidly transforms the biopharmaceutical industry, offering unprecedented opportunities to enhance efficiency, accuracy, and innovation. However, as AI becomes increasingly integrated into GMP-regulated processes, traditional quality management approaches must be rethought. This article delves into the critical aspects of GMP quality compliance in the AI era. It explores the top five reasons why
Good Manufacturing Practice (GMP) quality compliance is a cornerstone of the biopharmaceutical industry, ensuring that products are consistently produced and controlled according to high standards. As artificial intelligence (AI) and machine learning (ML) find increasing applications across the sector, it’s essential to consider how quality management processes need to evolve. Incorporating AI into biopharmaceuticals can
N-nitrosamine impurities, a class of potentially carcinogenic substances, have become a significant concern in the pharmaceutical industry. These compounds can form during the drug manufacturing process or due to degradation.
As technology continues to advance, the integration of artificial intelligence (AI) into GMP environments promises enhanced efficiency, productivity, and quality control. However, alongside these benefits come unique challenges and considerations, particularly concerning regulatory compliance.
Restricted Access Barrier Systems (RABS) have emerged as a cutting-edge technology to address challenges, providing a robust solution for aseptic processing in pharmaceutical and biotechnology industries. In this article, we will delve into what RABS technologies are and explore the steps involved in their successful implementation.